Outlook Therapeutics Appoints Bob Jahr as Chief Executive Officer
Published on July 2, 2025
ISELIN, N.J.—Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, has announced the appointment of Bob Jahr as its chief executive officer (CEO), effective immediately. Jahr has also been appointed to the Outlook Therapeutics board of directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics’ chief financial officer (CFO) and interim CEO, will continue serving as CFO and as a member of the board of directors, according to the announcement.